Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation

NCT00589563 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00589563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00589563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
February 29, 2012
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, graft versus host disease, infection, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, precancerous condition, secondary myelofibrosis, small intestine cancer